Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 301 people in one group and 297 in another — a total of 598 participants. The trial compared two different chemotherapy combinations, both given alongside radiation therapy, in people with a type of lung cancer. One group received pemetrexed plus cisplatin with radiation (Arm A), and the other received etoposide plus cisplatin with radiation (Arm B). The trial was primarily measuring how long participants lived overall, and also tracked how long they lived without their disease getting worse, how many showed a measurable reduction in tumour size, and their chances of surviving at one, two, and three years. The reported data shows that the median overall survival — that is, the point in time by which half the participants had died — was approximately 26.8 months in Arm A and approximately 25.0 months in Arm B. For progression-free survival (how long participants lived without their disease getting worse), the reported figures were approximately 11.4 months in Arm A and approximately 9.8 months in Arm B. When it came to tumour response, about 35.9% of participants in Arm A and 33.0% in Arm B showed a measurable reduction in tumour size. The reported survival probabilities at one, two, and three years were very similar between the two groups: roughly 76–77% of participants in both groups were estimated to be alive at one year, around 52% at two years, and approximately 40% (Arm A) and 37% (Arm B) at three years. The reported data also shows information about deaths that occurred while participants were on the study drug or within 30 days of stopping treatment, though the breakdown across the multiple reported categories was not straightforward to summarise from the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lung Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must have a specific type of lung cancer (non-squamous, non-small cell lung cancer) that is at Stage IIIA or Stage IIIB.
- Your cancer must be measurable using scans, such as a CT scan.
- You must be able to take care of yourself, move around, and do light activities like housework or office work.
- You must be 18 years of age or older.
- You must not have lost more than 10% of your body weight in the past 3 months.
- Women must not be able to become pregnant (either naturally or through use of contraception), and men must either be unable to father children or use contraception.
- Your blood, kidney, liver, and lung function test results must be at an acceptable level.
- If you have Stage IIIB lung cancer with swollen lymph nodes just above the collarbone (but not in the neck area), you may still be eligible — the trial site can confirm this based on your specific scan results (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You cannot join if you have other serious uncontrolled health conditions, such as an active infection, an unstable heart condition, or an uncontrolled mental health illness.
- You cannot join if you are unable to take vitamins (including vitamin B12 injections) or a steroid medication taken by mouth.
- You cannot join if you have had a heart attack or certain heart problems in the past 6 months.
- You cannot join if you have taken part in another clinical drug trial in the last 30 days.
- You cannot join if you take more than 1.3 grams of aspirin daily or take anti-inflammatory pain medicines (such as ibuprofen) and are unable to stop taking them.
- You cannot join if your cancer is the type that is usually treated with surgery (such as Pancoast or superior sulcus tumors).
- You cannot join if you have previously had radiation treatment to the chest area; however, radiation to other parts of the body may be acceptable if it was completed at least 30 days before the trial and you have fully recovered (confirm with trial site).
- You cannot join if your planned radiation treatment would expose more than 35% of your total lung volume to a high dose of radiation (confirm with trial site).
- You cannot join if you have had another type of cancer requiring treatment in the past 5 years, though some exceptions may be made on a case-by-case basis; certain treated skin cancers or very early-stage cancers may be allowed (confirm with trial site).
- You cannot join if your lung cancer has come back after surgery, or if you have a second new lung cancer.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 3 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Overall Survival
Other options
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.